One important change is that they state, GLP-1 RA therapy may be continued preoperatively in patients without elevated risk of delayed gastric emptying. The risk factors they state include: escalation phase of dosing, higher dose, weekly dosing (as opposed to daily dosing), gastrointestinal symptoms (nausea, vomiting, abdominal pain, dyspepsia, constipation), and medical conditions that may cause delayed gastric emptying
Clinical Diabetes , 41 (3), 467473.
The GLP-1 market represents a significant business opportunity for digital health solutions that can support behavior change among individuals with obesity and diabetes
7 Drinking enough water is essential, so ensure you are getting enough of it
doi: 10.3389/FENDO.2021.721135/XML/NLM 7 HolstJJ